ACADIA Pharmaceuticals (NASDAQ:ACAD) Rating Lowered to Sell at BidaskClub

BidaskClub downgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from a hold rating to a sell rating in a research report sent to investors on Friday, BidAskClub reports.

A number of other analysts have also issued reports on the stock. ValuEngine lowered shares of Zosano Pharma from a buy rating to a hold rating in a research report on Wednesday, May 1st. JPMorgan Chase & Co. set a €28.20 ($32.79) target price on shares of AXA and gave the stock a buy rating in a research report on Thursday, May 2nd. Raymond James restated a buy rating on shares of Kelt Exploration in a research report on Friday, May 31st. Zacks Investment Research upgraded shares of Flagstar Bancorp from a hold rating to a buy rating and set a $38.00 target price on the stock in a research report on Monday, July 8th. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $37.00 price target on shares of Vocera Communications in a report on Thursday, April 25th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. ACADIA Pharmaceuticals presently has an average rating of Buy and a consensus price target of $32.31.

Shares of NASDAQ ACAD opened at $25.97 on Friday. ACADIA Pharmaceuticals has a 1 year low of $12.77 and a 1 year high of $28.67. The stock’s 50 day moving average price is $26.14. The firm has a market capitalization of $3.71 billion, a price-to-earnings ratio of -13.39 and a beta of 2.88. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.29 and a current ratio of 6.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.05). ACADIA Pharmaceuticals had a negative return on equity of 79.74% and a negative net margin of 116.10%. The firm had revenue of $62.90 million for the quarter, compared to analyst estimates of $60.93 million. During the same quarter last year, the business posted ($0.44) EPS. The firm’s revenue was up 28.6% compared to the same quarter last year. Analysts anticipate that ACADIA Pharmaceuticals will post -1.9 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the business. JGP Global Gestao de Recursos Ltda. boosted its holdings in shares of ACADIA Pharmaceuticals by 92.3% in the 2nd quarter. JGP Global Gestao de Recursos Ltda. now owns 17,697 shares of the biopharmaceutical company’s stock valued at $473,000 after purchasing an additional 8,494 shares during the last quarter. Metropolitan Life Insurance Co NY lifted its holdings in shares of ACADIA Pharmaceuticals by 11.0% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 35,921 shares of the biopharmaceutical company’s stock valued at $964,000 after acquiring an additional 3,564 shares in the last quarter. MetLife Investment Advisors LLC lifted its holdings in shares of ACADIA Pharmaceuticals by 8.4% during the 1st quarter. MetLife Investment Advisors LLC now owns 49,671 shares of the biopharmaceutical company’s stock valued at $1,334,000 after acquiring an additional 3,852 shares in the last quarter. Clearbridge Investments LLC acquired a new position in shares of ACADIA Pharmaceuticals during the 1st quarter valued at $27,000. Finally, SG3 Management LLC acquired a new position in shares of ACADIA Pharmaceuticals during the 1st quarter valued at $201,000. Institutional investors own 93.33% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Featured Story: How do CD ladders protect against rising interest rates?

Analyst Recommendations for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit